SCHEMBL29460291

SCHEMBL29460291

O=C(NC12CC(C(F)(F)F)(C1)C2)c1cccc(F)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 1/20 0.51
▸ HDAC6 Q9UBN7 1/20 0.51
▸ IDO1 P14902 3/20 0.51
▸ GRM5 P41594 4/20 0.47
▸ FPR2 P25090 3/20 0.47
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ CES2 O00748 1/20 0.45
▸ CES1 P23141 1/20 0.45
▸ KCNK3 O14649 1/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ NPC1 O15118 3/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29460251 0.84 NPSR1 (0.52) MEN1KMT2ACES2KCNK3RAB9A
SCHEMBL23141420 0.83 FAAH (0.53) HDAC1HDAC6IDO1MEN1KMT2A
SCHEMBL31046923 0.82 IDO1 (0.46) IDO1MEN1KMT2ANPC1RAB9A
SCHEMBL29460313 0.81 IDO1 (0.52) IDO1CES2CES1NPC1RAB9A
SCHEMBL31046974 0.80 SMN1; SMN2 (0.48) IDO1MEN1KMT2AL3MBTL1NPC1
SCHEMBL31046913 0.80 KAT6A (0.44) IDO1GRM5FPR2KMT2A
SCHEMBL1579002 0.76 FAAH (0.60) HDAC1HDAC6GRM5FPR2MEN1
SCHEMBL29460215 0.76 KDM4E (0.49) KMT2ACES2CES1NPC1RAB9A
SCHEMBL2638136 0.75 FAAH (0.72) HDAC1HDAC6GRM5MEN1KMT2A
SCHEMBL23877633 0.75 HDAC1 (0.38) HDAC1IDO1CES2CES1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 — — US disclosed
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO, INC. 2024-12-12 — — US disclosed
CN-118791407-A Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives 奥索生物公司 2024-10-18 — — CN disclosed
CN-118638096-A Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives 奥索生物公司 2024-09-13 — — CN disclosed
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2024-07-30 — — US disclosed
CN-112204008-B Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives 奥索生物公司 2024-07-05 — — CN disclosed
EP-3796975-B1 SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO INC (US) 2023-08-30 — — EP disclosed
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES GILEAD SCIENCES, INC. 2022-02-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B HDAC1 1158/4885HDAC6 671/4885IDO1 3017/4885
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B HDAC1 1158/4885HDAC6 671/4885IDO1 3017/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 HDAC1 877/4885HDAC6 1063/4885IDO1 3639/4885
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B HDAC1 1158/4885HDAC6 671/4885IDO1 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback